NovoCure (NVCR) General Counsel receives new stock options and RSU grants

Rhea-AI Filing Summary

NovoCure Ltd reported that its General Counsel, Ben Arye Barak, received new equity awards. He was granted stock options for 73,340 ordinary shares at an exercise price of $0.00 per share, bringing his total options reported in this line to 73,340.

He also acquired 50,125 ordinary shares in the form of restricted share units at $0.00 per share, increasing his directly held ordinary shares to 242,453. The restricted share units are scheduled to vest in three equal annual installments on the first, second and third anniversaries of the grant date, subject to his continued employment. The options are scheduled to vest in four equal annual installments on the first, second, third and fourth anniversaries of the grant date, also subject to continued employment.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Ben Arye Barak

Role General Counsel

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	73,340	$0.00	--
Grant/Award	Ordinary Shares	50,125	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 73,340 shares (Direct); Ordinary Shares — 242,453 shares (Direct)

Footnotes (1)

1. Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates. Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ben Arye Barak

(Last) (First) (Middle)

C/O NOVOCURE INC.

1550 LIBERTY RIDGE DRIVE, SUITE 115

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NovoCure Ltd [ NVCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	03/03/2026		A		50,125	A	$0.00	242,453	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$13.3	03/03/2026		A		73,340		(2)	03/03/2036	Ordinary Shares	73,340	$0.00	73,340	D

Explanation of Responses:

1. Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates.

2. Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date.

Remarks:

	Steven Robbins, as attorney in fact for Ben Arye, Barak	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did NovoCure (NVCR) report for Ben Arye Barak?

NovoCure reported that General Counsel Ben Arye Barak received equity awards on the transaction date. He was granted 73,340 stock options and 50,125 restricted share units, both at an effective price of $0.00 per share as compensation.

How many NovoCure (NVCR) stock options were granted to the General Counsel?

The General Counsel received 73,340 stock options labeled as a “Stock Option (Right to Buy)”. These options vest in four equal annual installments on each of the first four anniversaries of the grant date, conditioned on his continued employment with NovoCure.

What restricted share units did NovoCure (NVCR) grant to its General Counsel?

NovoCure granted 50,125 restricted share units to its General Counsel. These RSUs are scheduled to vest in three equal parts on the first, second and third anniversaries of the grant date, provided he remains employed through each applicable vesting date.

How many NovoCure (NVCR) ordinary shares does the General Counsel hold after this Form 4?

After the reported grant of restricted share units, the General Counsel is shown as directly owning 242,453 ordinary shares. This figure reflects his total direct ordinary share holdings following the 50,125-share RSU acquisition reported in the filing.

What is the nature of the transactions in this NovoCure (NVCR) Form 4?

Both transactions are coded as “A”, indicating a grant, award, or other acquisition. They represent compensation-related equity awards, not open-market purchases or sales, and are classified as direct ownership by the reporting person following the grants.

How do the vesting terms work for NovoCure (NVCR) equity awards to the General Counsel?

The restricted share units vest in three equal annual tranches over three years. The stock options vest in four equal annual tranches over four years. In both cases, vesting is contingent on the General Counsel’s continued employment through each vesting date.